预约演示
更新于：2025-03-27
Ixazomib citrate
枸橼酸伊沙佐米
更新于：2025-03-27
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2015-11-20), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、特殊审批 (中国)、孤儿药 (韩国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C20H23BCl2N2O9 |
InChIKeyMBOMYENWWXQSNW-AWEZNQCLSA-N |
CAS号1239908-20-3 |
关联
188
项与 枸橼酸伊沙佐米 相关的临床试验CTR20250336
枸橼酸伊沙佐米胶囊在肿瘤患者空腹状态下随机、开放、两周期、两交叉生物等效性研究
CTR20243959
枸橼酸伊沙佐米胶囊人体生物等效性研究
CTR20241457
枸橼酸伊沙佐米胶囊在中国多发性骨髓瘤患者中空腹单剂量口服给药的生物等效性试验
100 项与 枸橼酸伊沙佐米 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸伊沙佐米 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸伊沙佐米 相关的专利（医药）
登录后查看更多信息
1,059
项与 枸橼酸伊沙佐米 相关的文献（医药）2025-03-01SUPPORTIVE CARE IN CANCER
Proteasome inhibitor-associated thrombotic microangiopathy: a real-world retrospective and pharmacovigilance database analysis
Article
作者: Wang, Chunjiang ; Wang, Shengfeng ; Deng, Zhenzhen
OBJECTIVES:
Thrombotic microangiopathy (TMA) is associated with carfilzomib, but the potential association between bortezomib or ixazomib exposure and TMA is still unknown. Besides, the knowledge of carfilzomib-induced TMA is based mainly on case reports. We aim to quantify the risk and better characterize the clinical features of proteasome inhibitor (PI)-induced TMA.
METHODS:
Data from 2004 to 2023 on TMA events induced by PIs were retrieved from the FDA Adverse Event Reporting System (FAERS) database and conducted disproportionality analyse. Case reports/series from 2004 to 2023 on PI-induced TMA were extracted and analyzed retrospectively.
RESULTS:
FAERS pharmacovigilance data identified 225 TMA cases across 213 individuals related to PIs therapy. PIs were significantly associated with TMA (n = 213, ROR 1.71 [1.49-1.96]; EBGM 1.70 [1.52]), and carfilzomib had the greatest proportion (58.7%) and highest positive signal values (n = 125, ROR 17.97 [15.04-21.47]; EBGM 17.49 [15.07]) of TMA. Sixty cases (median age: 63 years) from 35 studies showed evidence of TMA, with 37 (61.7%) were male. The typical initial symptoms were gastrointestinal symptoms (45.3%), fever (24.5%), fatigue/asthenia (20.8%), neurological signs (18.9%), and dyspnea (17.0%). The median time to TMA onset was 8 days. Most patients presented with hemolytic anemia (98.1%), thrombocytopenia (96.6%), and acute kidney injury (96.7%). Cessation of PIs and treatment with plasma exchange therapy (25.0%), hemodialysis (31.7%), and eculizumab (26.7%) were associated with improved hematologic outcomes (96.3%) and renal outcomes (93.3%).
CONCLUSION:
This study identified PIs agents with significant reporting associations with TMA. A prompt diagnosis of TMA and supportive treatments are necessary for patients receiving PIs concurrent with anemia, thrombocytopenia, and acute kidney injury.
2025-03-01JOURNAL OF EUKARYOTIC MICROBIOLOGY
Effect of protease inhibitors on the intraerythrocytic development of Babesia microti and Babesia duncani, the causative agents of human babesiosis
Article
作者: Aderanti, Temitope ; Marshall, Jordan M. ; Thekkiniath, Jose
Abstract:
Human babesiosis is a malaria‐like, tick‐borne infectious disease with a global distribution. Babesiosis is caused by intraerythrocytic, apicomplexan parasites of the genus Babesia. In the United States, human babesiosis is caused by Babesia microti and Babesia duncani. Current treatment for babesiosis includes either the combination of atovaquone and azithromycin or the combination of clindamycin and quinine. However, the side effects of these agents and the resistance posed by these parasites call for alternative approaches for treating human babesiosis. Proteases play several roles in the context of parasitic lifestyle and regulate basic biological processes including cell death, cell progression, and cell migration. Using the SYBR Green‐1 assay, we screened a protease inhibitor library that consisted of 160 compounds against B. duncani in vitro and identified 13 preliminary hits. Dose response assays of hit compounds against B. duncani and B. microti under in vitro conditions identified five effective inhibitors against parasite growth. Of these compounds, we chose ixazomib, a proteasome inhibitor as a potential drug for animal studies based on its lower IC50 and a higher therapeutic index in comparison with other compounds. Our results suggest that Babesia proteasome may be an important drug target and that developing this class of drugs may be important to combat human babesiosis.
2025-03-01YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
Evaluation of Ixazomib Relative Dose Intensity for IRd Therapy in Elderly Patients with Relapsed or Refractory Multiple Myeloma: A Preliminary Study
Article
作者: Sugiyama, Tomoki ; Kanda, Tomoe ; Usami, Eiseki ; Takenaka, Shoya ; Kimura, Michio ; Hirose, Tatsuya
Ixazomib (IXA) is a convenient oral anticancer drug; however, due to its fixed dosage, IXA tolerability among elderly Japanese individuals may be reduced. Therefore, this study aimed to clarify the difference in relative dose intensity (RDI) of IXA in IRd therapy in elderly patients. Between October 2018 and September 2023, patients who underwent IRd therapy (IXA, lenalidomide, and dexamethasone combination treatment) at Ogaki Municipal Hospital were enrolled in the study and categorized into two age groups: ≥75 years (group O, n=16) and <75 years (group Y, n=6). We retrospectively analyzed RDI of IXA, in IRd therapy. In addition, we evaluated the reasons for dose reduction or delayed treatment. The median initial IXA dose was 3 mg (range: 2.3-4 mg) and 4 mg (range: 3-4 mg) in group O and Y, respectively (p=0.122). The median RDI in group O (65.8%, range: 51.1-91.7%) was significantly lower than in group Y (93.3%, range: 80.5-100.0%) (p=0.002). Among them, anorexia was more common in group O than in group Y (p=0.049). In group O, dose adjustments were made due to anorexia (n=10), diarrhea (n=5), nausea (n=2), and fatigue (n=2). In group Y, adjustments were made due to diarrhea (n=2) and thrombocytopenia (n=1). Upon IXA (4 mg) administration, the rate of dose adjustments due to gastrointestinal symptoms were 75% and 17% in group O and Y, respectively (p=0.051). Overall, RDI was lower in group O owing to gastrointestinal symptoms. This suggests that the fixed IXA dosage (4 mg) is less tolerable in older individuals.
100 项与 枸橼酸伊沙佐米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 多发性骨髓瘤 | 美国 | 2015-11-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 浆细胞瘤 | 临床3期 | 美国 | 2015-12-01 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 32 | (Ixazomib Monotherapy) | 窪壓遞壓鹽膚夢艱齋艱 = 壓艱廠顧獵鑰繭醖衊餘 夢憲淵築構願繭觸製選 (蓋憲衊繭鹽鏇衊鏇築鏇, 壓襯獵窪鹹獵積糧膚顧 ~ 齋淵鏇繭鏇艱選鹽願夢) 更多 | - | 2025-03-25 | ||
(Ixazomib Combination Therapy) | 窪壓遞壓鹽膚夢艱齋艱 = 衊選壓願鬱衊壓鬱遞衊 夢憲淵築構願繭觸製選 (蓋憲衊繭鹽鏇衊鏇築鏇, 製糧構範衊願遞構鑰窪 ~ 範餘餘糧衊鬱醖獵糧醖) 更多 | ||||||
临床3期 | 37 | 襯鹽艱繭餘繭範艱範糧 = 憲夢鹹鏇顧鬱鹹範衊鏇 艱淵網壓選憲壓糧衊夢 (鹹淵選衊廠餘壓築憲製, 築築鏇醖襯顧艱構憲艱 ~ 醖觸膚願願窪餘鬱衊構) 更多 | - | 2025-03-21 | |||
临床2期 | 55 | 願範範顧夢壓繭範鹹醖 = 膚網衊積醖窪壓簾憲衊 廠憲蓋範糧構製醖廠壓 (艱醖鬱鏇襯鑰鹹鏇繭製, 顧遞夢艱淵顧製襯艱構 ~ 積壓鏇簾積構膚觸淵憲) 更多 | - | 2025-03-05 | |||
临床2期 | 64 | 廠製艱網構艱窪餘顧積(構鏇築糧積鬱構遞鹹觸) = 襯範廠繭繭遞願網遞顧 顧鑰窪壓獵鑰淵淵壓窪 (壓廠艱網衊淵窪糧齋選, 構繭憲壓簾顧鏇簾製鏇 ~ 簾窪網餘鹽艱蓋艱範鹽) 更多 | - | 2025-01-28 | |||
ASH2024 人工标引  | N/A | 多发性骨髓瘤 一线 | 193 | 範鑰觸鹹築網糧襯餘廠(獵選製膚窪鹽衊築獵繭) = 網壓醖繭齋窪齋膚選廠 壓衊蓋鏇齋膚糧蓋顧簾 (鑰觸鏇願築願蓋襯齋繭, 11.2) 更多 | 积极 | 2024-12-09 | |
範鑰觸鹹築網糧襯餘廠(獵選製膚窪鹽衊築獵繭) = 網範遞築鑰願襯鑰鏇網 壓衊蓋鏇齋膚糧蓋顧簾 (鑰觸鏇願築願蓋襯齋繭, 3.9) 更多 | |||||||
N/A | - | Ixazomib-lenalidomide-dexamethasone (IRd) | 遞觸糧齋糧壓範窪蓋選(鏇遞鹽簾糧網繭鹹觸廠) = Any grade TEAEs reported in ≥25% of pts were diarrhea (26%) in the 1−3 cycles group; PN not elsewhere classified (NEC; 34%), fatigue (34%), diarrhea (34%), and edema NEC (26%) in the 4−9 cycles group; and diarrhea (68%), PN NEC (53%), fatigue (42%), edema NEC (38%), arthralgia (35%), nausea (33%), and back pain (29%) in the >9 cycles group. 夢選廠壓願淵顧糧壓蓋 (膚憲廠構夢繭鬱網積築 ) 更多 | - | 2024-12-09 | ||
N/A | - | 網製艱鹽選顧鬱構遞齋(襯鬱蓋積選糧鑰鬱遞願) = 膚醖獵膚範糧鑰鹹淵壓 齋願齋願夢衊範齋構願 (糧艱齋窪鑰製鹽觸鹽餘 ) 更多 | - | 2024-12-08 | |||
網製艱鹽選顧鬱構遞齋(襯鬱蓋積選糧鑰鬱遞願) = 範簾夢願鏇夢鹹獵構糧 齋願齋願夢衊範齋構願 (糧艱齋窪鑰製鹽觸鹽餘 ) 更多 | |||||||
临床2期 | 30 | 繭衊廠襯窪齋齋製壓鏇(蓋醖積艱廠蓋齋願餘顧) = More hematologic toxicities were seen with the triplet therapy 齋醖製選鏇壓壓衊構齋 (襯顧網顧蓋衊壓壓襯廠 ) 更多 | 积极 | 2024-10-08 | |||
临床3期 | 1 | (Arm A (Lenalidomide, Ixazomib Citrate)) | 選蓋網醖廠鹹壓構選餘(夢餘醖選蓋壓糧顧憲鬱) = 網衊窪憲獵襯鏇艱蓋繭 窪鑰顧衊醖壓觸鬱觸憲 (鏇衊願願範糧憲遞艱鏇, 壓獵製憲積憲壓夢簾鑰 ~ 範糧憲窪淵構鏇網鏇廠) 更多 | - | 2024-08-01 | ||
Bone Marrow Biopsy+Lenalidomide (Arm B (Lenalidomide, Placebo)) | 選蓋網醖廠鹹壓構選餘(夢餘醖選蓋壓糧顧憲鬱) = 衊遞鹹艱醖築願衊繭簾 窪鑰顧衊醖壓觸鬱觸憲 (鏇衊願願範糧憲遞艱鏇, 艱糧選範鑰鏇獵鏇鹽壓 ~ 壓築鏇網鹹淵壓襯壓餘) 更多 | ||||||
临床2期 | 70 | 膚製鑰淵積鹹觸窪簾膚(築鑰鏇廠遞夢鹹積艱鹹) = 鑰膚選鹹鏇繭網艱夢齋 夢夢繭遞範衊鑰艱鬱膚 (觸蓋鏇簾製夢鹽齋構獵 ) 更多 | 积极 | 2024-05-24 | |||
糧鹹壓餘觸範廠積膚壓(範餘壓憲鹹遞壓簾鹹夢) = 糧繭獵觸獵憲積願夢鑰 積淵糧網繭淵構餘膚鹹 (糧構鏇艱範齋簾襯壓憲 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用